Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00522275 · ClinicalTrials.gov registry record · Phase 3
Determine Safety and Efficacy of Long-term Oral Lacosamide in Patients With Partial Seizures
A Phase 3 study, sponsored by UCB Biosciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 308
- Enrollment target
NCT00522275 is a Phase 3 study that has completed, run by UCB Biosciences. The registered enrollment target is 308 participants.
The verdict
NCT00522275, a Phase 3 study, has completed, sponsored by UCB Biosciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 308 participants
- Enrollment target
Study Summary
The purpose of this trial is to determine whether lacosamide is safe and effective for long-term use in patients with partial-seizures from epilepsy
Interventions
- DRUG lacosamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 308 participants |
| Start Date | 2004-10 |
| Est. Completion | 2009-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00522275
The ClinicalTrials.gov registry entry for NCT00522275 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 308 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Biosciences, which has 39 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which lacosamide is the first listed.
NCT00522275 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00522275 about?
NCT00522275 is a clinical study titled "Determine Safety and Efficacy of Long-term Oral Lacosamide in Patients With Partial Seizures". The purpose of this trial is to determine whether lacosamide is safe and effective for long-term use in patients with partial-seizures from epilepsy
What is the current status of trial NCT00522275?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 308 participants. The study started on 2004-10. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00522275?
The interventions under investigation include: lacosamide (DRUG).
Who is sponsoring clinical trial NCT00522275?
This trial is sponsored by UCB Biosciences, which has 39 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.